Abaloparatide vs Bivalirudin
Overview
Abaloparatide is primarily a bone & joint peptide, while Bivalirudin is used for cardiovascular.
This page compares Abaloparatide and Bivalirudin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Abaloparatide | Bivalirudin | |
|---|---|---|
| Category | Bone & Joint | Cardiovascular |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 80 mcg | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion |
| Frequency | daily | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours |
| Reported benefits | Bone building, osteoporosis treatment, reduced fracture risk | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin |
| Reported side effects | Similar to teriparatide but milder | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) |
Key differences
Primary use. Abaloparatide is categorised under Bone & Joint, while Bivalirudin falls under Cardiovascular. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Abaloparatide: FDA-approved. Bivalirudin: FDA-approved.
Dosing. Abaloparatide is typically dosed at 80 mcg (daily). Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours).
Can you stack them?
Some protocols combine peptides, but stacking Abaloparatide and Bivalirudin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Abaloparatide and Bivalirudin?
- Abaloparatide is primarily a bone & joint peptide, while Bivalirudin is used for cardiovascular. Abaloparatide is FDA-approved for one or more indications, whereas Bivalirudin is FDA-approved for one or more indications.
- What is Abaloparatide used for?
- Advanced bone anabolic.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- Can you take Abaloparatide and Bivalirudin together?
- Some users combine peptides within a single protocol, but stacking Abaloparatide and Bivalirudin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Abaloparatide or Bivalirudin FDA-approved?
- Abaloparatide is FDA-approved for one or more indications. Bivalirudin is FDA-approved for one or more indications.
Read the full articles
- Abaloparatide — full monograph: mechanism, research, dosing & references
- Bivalirudin — full monograph: mechanism, research, dosing & references